Bioavailability of butorphanol after intranasal administration to horses

The aim of the present study was to describe butorphanol pharmacokinetics and bioavailability following intranasal administration to horses. Six adult horses received 0.05 mg/kg butorphanol, in a randomised crossover design, by either intravenous or intranasal route. Plasma concentrations of bu-torp...

Full description

Bibliographic Details
Authors: Ferreira, V., Velloso, María Inés, Landoni, Maria Fabiana
Format: article
Status:Published version
Publication Date:2020
Country:Argentina
Institution:Consejo Nacional de Investigaciones Científicas y Técnicas
Repository:CONICET Digital (CONICET)
Language:English
OAI Identifier:oai:ri.conicet.gov.ar:11336/134751
Online Access:http://hdl.handle.net/11336/134751
Access Level:Open access
Keyword:BIOAVAILABILITY
BUTORPHANOL
HORSES
INTRANASAL
PHARMACOKINETICS
https://purl.org/becyt/ford/4.3
https://purl.org/becyt/ford/4
Description
Summary:The aim of the present study was to describe butorphanol pharmacokinetics and bioavailability following intranasal administration to horses. Six adult horses received 0.05 mg/kg butorphanol, in a randomised crossover design, by either intravenous or intranasal route. Plasma concentrations of bu-torphanol were measured at predetermined time points using liquid chromatography/mass spectrome-try assay. After intravenous injection, mean ±SD butorphanol steady-state volume of distribution and clearance was 3.20 ± 1.77 L/kg and 3.18 ± 1.47 L/kg/h, respectively. Terminal half-lives for butor-phanol after intravenous and intranasal administrations were 0.68 ± 0.17 h and 1.79 ± 1.43 h. For intranasal administration, absorption half-life and peak plasma concentration were 0.43 ± 0.33 h and 1.95 ± 1.7 ng/mL, respectively. Bioavailability was 54.45 ± 20.09%. Intranasal butorphanol administration in horses is practical, not stressful and well tolerated. Therefore, it might be a substitute to the intravenous route in adult horses.